HURA

TuHURA Biosciences Inc

2.09

Oct 21 • 3:59 PM ET +0.33 (18.47%)

2.25

Aftermarket • 7:59 PM ET +0.16 (7.91%)

Healthcare Biotechnology USA Micro NASD

Peers: GNLX CADL REPL PDSB CUE ONCY MAIA IOVA CRVS KZIA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	132.87M
Enterprise Value	136.16M
Income	-30.63M
Sales	0.00M
Book/sh	0.29
Cash/sh	0.02
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	22
IPO	Feb 22, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.29
P/C	132.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.18
Current Ratio	0.18
Debt/Eq	0.22
LT Debt/Eq	0.20
Option/Short	No / Yes

EPS (ttm)	-0.53
EPS next Y	-0.61
EPS next Q	-0.14
EPS this Y	12.70%
EPS next Y	-11.82%
EPS next 5Y	-
EPS past 3/5Y	87.54% 81.38%
Sales past 3/5Y	- -
EPS Y/Y TTM	84.80%
Sales Y/Y TTM	-
EPS Q/Q	32.55%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	8.68% -

Insider Own	34.62%
Insider Trans	0.00%
Inst Own	14.40%
Inst Trans	-2.19%
ROA	-92.29%
ROE	-161.39%
ROIC	-137.37%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	7.68%
SMA50	1.51%
SMA200	8.29%
Trades

Shs Outstand	63.68M
Shs Float	41.66M
Short Float	14.63%
Short Ratio	27.83
Short Interest	6.10M
52W High	3.43 -39.21%
52W Low	0.41 408.54%
Volatility	10.06% 6.39%
ATR (14)	0.13
RSI (14)	57.41
Beta	-0.24
Rel Volume	4.93
Avg Volume	219.04K
Volume	1,079,489

Perf Week	18.47%
Perf Month	-2.11%
Perf Quarter	-3.02%
Perf Half Y	-22.20%
Perf YTD	175.54%
Perf Year	-9.74%
Perf 3Y	-98.51%
Perf 5Y	-99.87%
Perf 10Y	-100.00%
Recom	1.00
Target Price	8.04
Prev Close	1.76
Price	2.09
Change %	18.47%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-26	Initiated	Citizens	Mkt Outperform	$9
Mar-03-25	Initiated	H.C. Wainwright	Buy	$13
Dec-19-24	Initiated	Rodman & Renshaw	Buy	$11
Nov-05-24	Initiated	Maxim Group	Buy	$15

Oct-13-26 07:45AM	TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 (PR Newswire)
Oct-05-26 07:45AM	TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology (PR Newswire)
Sep-14-26 07:45AM	TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers (PR Newswire)
Sep-08-26 07:45AM	TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
Aug-14-26 07:45AM	TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update (PR Newswire) +7.39%
07:40AM	Loading…
Jul-22-26 07:40AM	TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference (PR Newswire)
May-15-26 05:00PM	TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update (PR Newswire) -7.97% +10.39%
May-12-26 07:30AM	TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference (PR Newswire)
Apr-22-26 07:30AM	TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 (PR Newswire)
Apr-07-26 07:45AM	TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations (PR Newswire)
Apr-01-26 07:45AM	TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (PR Newswire) -9.50%
Mar-27-26 08:05AM	These 16 stocks are a short seller's dream - likely losers no matter what the market does (MarketWatch) -7.18%
Mar-24-26 10:30AM	Advancements in Novel Immunotherapeutics in The Oncology Battle (Newsfile)
Mar-23-26 07:45AM	Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers (PR Newswire)
Feb-27-26 07:30AM	TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
05:20PM	Loading…
Feb-24-26 05:20PM	TuHURA Biosciences Announces Participation in Upcoming Investor Conferences (PR Newswire) +12.90% +20.00%
Feb-12-26 07:45AM	TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (PR Newswire) +7.75%
Feb-02-26 07:45AM	TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma (PR Newswire)
Dec-15-25 07:50AM	TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone (PR Newswire) -6.01%
Dec-11-25 07:30AM	TuHURA Biosciences Provides Corporate Update Following Recent Financing (PR Newswire)
Dec-09-25 09:49AM	TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering (PR Newswire) -40.91%
Dec-08-25 07:50AM	TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition (PR Newswire)
Nov-14-25 07:00AM	TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
Nov-03-25 09:01AM	TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition (PR Newswire)
Aug-20-25 08:00AM	TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference (PR Newswire)
Aug-14-25 04:15PM	TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire) +10.87%
Jul-01-25 08:50AM	TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000 and Russell 2000 Indexes (PR Newswire) +10.76%
Jun-30-25 08:50AM	TuHURA Biosciences Completes Acquisition of Kineta (PR Newswire)
Jun-24-25 08:00AM	TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma (PR Newswire) -7.11%
Jun-23-25 05:00PM	TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals (PR Newswire)
08:00AM	Loading…
Jun-09-25 08:00AM	FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma (PR Newswire)
Jun-03-25 09:58AM	TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy (PR Newswire) -6.09%
Jun-02-25 08:03AM	TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting (PR Newswire)
May-15-25 04:10PM	TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
May-13-25 08:00AM	TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference (PR Newswire) +7.33%
May-05-25 08:00AM	TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP) (PR Newswire)
Apr-28-25 08:00AM	TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting (PR Newswire)
Apr-18-25 03:26PM	Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts? (Insider Monkey)
Apr-08-25 08:00AM	TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting (PR Newswire)
Apr-07-25 08:24AM	TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management (PR Newswire) +7.69%
Apr-01-25 08:00AM	TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update (PR Newswire) -9.91%
Mar-11-25 08:05AM	TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors (ACCESSWIRE) +12.77%
Mar-10-25 09:00AM	TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference (ACCESS Newswire) -10.05%
Feb-19-25 09:00AM	TuHURA Biosciences, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (ACCESSWIRE) -12.88%
Dec-12-24 08:45AM	TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. (ACCESSWIRE) -7.88%
Nov-25-24 08:35AM	TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update (ACCESSWIRE) -10.64%
Oct-23-24 08:30AM	TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (ACCESSWIRE)
Oct-22-24 09:00AM	TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor 'New to the Street' Event (ACCESSWIRE) -5.01%
Oct-17-24 04:35PM	TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics (ACCESSWIRE) -6.31% -16.43%
Oct-16-24 12:54PM	Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024 (PR Newswire)
11:58AM	Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences (PR Newswire)
Oct-15-24 04:15PM	Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 (PR Newswire) +14.70%
Oct-14-24 08:30AM	Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 (PR Newswire) +11.30%
Oct-09-24 07:28AM	Kintara Therapeutics Reveals Improved Financials, Merger Plans (TipRanks)
Oct-08-24 07:00AM	Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update (PR Newswire)
Sep-20-24 09:25AM	Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 (PR Newswire)
Sep-18-24 08:30AM	Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences (PR Newswire) -8.42%
Sep-11-24 08:30AM	Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study (PR Newswire)
Sep-09-24 08:30AM	Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. (PR Newswire)
Aug-19-24 09:00AM	TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer (PR Newswire) +8.16%
Jul-08-24 06:30AM	TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor (PR Newswire) -6.83%
Jul-01-24 08:35AM	Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones (PR Newswire) +10.14%
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -10.11%
Jun-03-24 08:35AM	TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) (PR Newswire) -12.66%
May-30-24 07:47AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +16.54%
May-20-24 07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +22.38%
May-14-24 10:53PM	KTRA Stock Earnings: Kintara Therapeutics Reported Results for Q3 2024 (InvestorPlace) -7.25%
04:45PM	Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results (PR Newswire)
Apr-04-24 10:38AM	Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA (Zacks) -12.38%
Apr-03-24 09:46AM	Why Is Kintara Therapeutics (KTRA) Stock Up 103% Today? (InvestorPlace) +63.35%
07:00AM	Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement (PR Newswire)
Mar-27-24 09:00AM	Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab (PR Newswire)
Feb-14-24 04:07PM	Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update (PR Newswire)
Feb-12-24 09:00AM	Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer (PR Newswire) -5.22%
Dec-07-23 09:00AM	Kintara Therapeutics Announces Review of Strategic Alternatives (PR Newswire) -6.85%
Dec-05-23 09:00AM	Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement (PR Newswire) -10.66%
Nov-13-23 04:10PM	Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update (PR Newswire)
Oct-31-23 08:00AM	Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study (PR Newswire) -79.68%
Oct-11-23 08:00AM	Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference (PR Newswire) +8.81%
Oct-02-23 08:00AM	Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference (PR Newswire)
Sep-25-23 07:30AM	Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting (PR Newswire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-18-23 04:25PM	Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update (PR Newswire) -11.54% +8.97%
Sep-05-23 08:00AM	Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting (PR Newswire)
Aug-17-23 05:00PM	Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023 (PR Newswire)
Aug-09-23 08:16AM	Kintara Therapeutics to Present at the Emerging Growth Conference (PR Newswire)
Aug-08-23 07:00AM	Presenting on the Emerging Growth Conference on August 9 & 10 Register Now (GlobeNewswire)
Jul-19-23 08:00AM	Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C. (PR Newswire)
Jun-30-23 11:07AM	Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy (Zacks)
Jun-28-23 04:15PM	Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001 (PR Newswire) +40.80%
Jun-16-23 08:00AM	Kintara Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference (PR Newswire)
May-19-23 08:30AM	Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society (PR Newswire)
May-11-23 08:15AM	Kintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate Update (PR Newswire) -6.74%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-08-23 08:30AM	Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference (PR Newswire) -5.04%
May-01-23 08:30AM	Kintara Therapeutics to Present at the Aegis Capital Virtual Conference (PR Newswire)
Apr-14-23 12:00PM	Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual Meeting (PR Newswire)
Mar-15-23 08:00AM	Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual Meeting (PR Newswire) +17.08%
Mar-10-23 08:30AM	Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023 (PR Newswire) -12.61%
Feb-14-23 05:00PM	Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update (PR Newswire)

Show Previous News

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. Its lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded by Michael Lawman, Patricia Lawman and James A. Bianco on May 4, 2023 and is headquartered in Tampa, FL.

PresidentDr. James A. Bianco M.D.

Executive VP of Finance & CFOMr. Dan Dearborn CPA

Co-FounderMr. Michael Lawman

Co-FounderMs. Patricia Lawman

Head of Quality AssuranceMr. Michael Krsulich

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HURA

TuHURA Biosciences Inc

Upgrade your Finviz experience